



In the Claims:

1. (Currently amended) A method of treating ocular hypertension which comprises administering to a mammal having ocular hypertension a therapeutically effective amount of a compound represented by formula II:




wherein the hatched segments represent α bonds, the solid triangle represents a β bond, wavy line attachments indicate either the alpha (α) or beta (β) configuration; dashed bonds represent a double bond or a single bond, R is a substituted hetero aryl radical, wherein the substituent is selected from the group consisting of C_4 to C_6 -alkyl, halogen, trifluoromethyl, COR¹, COCF₃, SO₂NR¹, NO₂ and CN; R¹ is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of -OR¹, -N(R¹)₂, and -N(R⁵)SO₂R⁶, wherein R⁵ represents hydrogen or CH₂OR⁶ and R⁶ represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical; Y is =O or represents 2 hydrogen radicals and the pharmaceutically acceptable salts and esters thereof.

2. (Cancelled)
3. (Original) A pharmaceutical product, comprising a container adapted to dispense the contents of said container in metered form; and an ophthalmic solution in said container comprising a compound of formula I as defined in Claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a non-toxic, ophthalmically acceptable liquid vehicle.
4. (Currently amended) A method of treating glaucoma which comprises administering to a mammal having glaucoma a therapeutically effective amount of a compound represented by formula I:




wherein the wavy segments represent either an alpha (α) or beta (β) bond; dashed bonds represent a double bond or a single bond, R is a substituted hetero aryl radical, wherein the substituent is selected from the group consisting of C_1 to C_6 alkyl, halogen, trifluoromethyl, COR^1 , $COCF_3$, SO_2NR^1 , NO_2 and CN ; R^1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of $-OR^1$, $-N(R^1)_2$, R^1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of $-OR^1$, $-N(R^1)_2$, and $-N(R^5)SO_2R^6$, wherein R^5 represents hydrogen or CH_2OR^6 and R^6 represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical; Y is $=O$ or represents 2 hydrogen radicals and the pharmaceutically acceptable salts and esters thereof.

5. (Original) The method of claim 4 wherein said compound is represented by formula II:



wherein the hatched segments represent α bonds and the triangular segment represents a β bond.

6. (Currently amended) A method of treating elevated intraocular pressure which comprises administering to a mammal having elevated intraocular pressure a therapeutically effective amount of a compound represented by formula I:



wherein the wavy segment represents either an α (α) or β (β) bond; dashed bonds represent a double bond or a single bond, R is a substituted hetero aryl radical, wherein the substituent is selected from the group consisting of C_1 -to- C_6 alkyl, halogen, trifluoromethyl, COR^1 , $COCF_3$, SO_2NR^1 , NO_2 and CN ; R^1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected

from the group consisting of $-OR^1$, $-N(R^1)_2$, R^1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of $-OR^1$, $-N(R^1)_2$, and $-N(R^5)SO_2R^6$, wherein R^5 represents hydrogen or CH_2OR^6 and R^6 represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical; Y is $=O$ or represents 2 hydrogen radicals and the pharmaceutically acceptable salts and esters thereof.